| Autor: |
Otto T; Urologische Klinik und Poliklinik, Medizinische Einrichtunger, Universität-Gesamthochschule Essen., Krege S, Goepel M, Baschek R, Rübben H |
| Jazyk: |
němčina |
| Zdroj: |
Der Urologe. Ausg. A [Urologe A] 1997 Jul; Vol. 36 (4), pp. 339-42. |
| DOI: |
10.1007/s001200050108 |
| Abstrakt: |
We present long-term results (minimum follow-up 5 years) in 145 patients with advanced non-seminomatous germ cell tumours, who underwent radical retroperitoneal lymphadenectomy (RPLA) after chemotherapy. We correlated patients' outcomes (death of disease) to different kinds of chemotherapy and to intraoperative findings. We found that patients who were treated by a modified Einhorn scheme with cisplatin, etoposide and bleomycin have a good prognosis. In all, 90% showed no evidence of disease (NED). The NED rate was significantly lower in patients who were treated by sequential alternative chemotherapy (DOD = 37%). We determined the following prognostic factors which predict a poor outcome: salvage RPLA in the case of progressive disease or tumour marker increase during chemotherapy (DOD = 89%, P < 0.0001) residual tumour in multiple-organ systems (DOD = 41%, P = 0.0006) vital tumour in RPLA specimen (DOD = 53%, P < 0.0001) residual tumour mass > 5 cm (DOD = 41%, P = 0.0188). We found that histopathological findings of the primary tumour and tumour stage IIc-IIIc according to the Lugano classification have no prognostic significance for death of disease. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full text from SpringerLink